GlobeNewswire Inc | Dec 1, 2021 08:49AM EST

December 01, 2021

LONDON, Dec. 01, 2021 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the Company or SmallPharma), a neuropharmaceutical company focused on psychedelic-assisted therapies, announces its participation in the H.C. Wainwright 2ndAnnual Psychedelics Conference, which is being held virtually on Monday, December 6, 2021. A webcast presentation hosted by Peter Rands, Small Pharmas Chief Executive Officer, will be available to view on demand beginning on December 6, 2021 at 7:00 a.m. ET. The webcast will also be made available on the Events and Conferences page of the Companys website.

Webcast Information: Presenter: Peter Rands, Chief Executive Officer Date: Monday, December 6th, 2021 Time: available on demandWebcast Link: Click Here

Virtual Meeting Availability: To schedule a one-on-one meeting with the Small Pharmas management team at the H.C. Wainwright Conference, please contact your appropriate representative directly, or email H.C. Wainwright at lk@hcwco.com.

About Small PharmaSmall Pharma is a neuropharmaceutical company specialized in IP led development of novel treatments for mental health conditions, with a focus on depression. Small Pharma initiated a clinical program into N,N-dimethyltryptamine (DMT) assisted therapy in February 2021. This program includes a Phase I/IIa trial on its lead candidate alongside development of a robust pipeline of proprietary preclinical assets.

About DMTDMT is a naturally occurring psychedelic tryptamine found in plants and in the brain of mammals. Scientific evidence suggests DMT offers the potential for rapid-acting and long-lasting antidepressant effects. DMT is differentiated by its short psychedelic experience (< 30mins), which allows for short treatment sessions and offers the potential for convenient supervised treatments within patient clinics. Small Pharma is advancing a pipeline of DMT-based therapies and is leading the worlds first DMT clinical trial for major depressive disorder, in collaboration with Imperial College London.

For further information contact:

Small Pharma Inc.Peter RandsChief Executive OfficerEmail: ir@smallpharma.co.ukTel: +44 (0)2071 129118

Media Relations ContactMcKenna MillerKCSA Strategic CommunicationsEmail: smallpharmapr@kcsa.comTel: +1 (949) 949-6585

Investor Relations ContactsEric RibnerLifeSci AdvisorsEmail: eric@lifesciadvisors.com

Tim Regan/Adam HoldsworthKCSA Strategic CommunicationsEmail: smallpharmair@kcsa.comTel: +1 (347) 487-6788

Cautionary NoteSmall Pharma makes no medical, treatment or health benefit claims about its proposed products. The UK Medicines and Healthcare products Regulatory Agency (MHRA) or other similar regulatory authorities have not evaluated claims regarding DMT-assisted therapies and other next generation psychoactive compounds. The efficacy of such therapies has not been confirmed by MHRA-approved research. There is no assurance that such DMT-assisted therapies and other psychoactive compounds can diagnose, treat, cure or prevent any disease or condition. Vigorous scientific research and clinical trials are needed. Any references to quality, consistency, efficacy and safety of potential therapies do not imply that Small Pharma verified such in clinical trials or that Small Pharma will complete such trials. If Small Pharma cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on Small Pharmas performance and operations.

The TSX Venture Exchange (the TSXV) has neither approved nor disapproved the contents of this news release. Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.